Open Access
SHS Web of Conf.
Volume 178, 2023
3rd International Conference on Public Relations and Social Sciences (ICPRSS 2023)
Article Number 03010
Number of page(s) 7
Section Corporate Marketing Strategy and Innovation Development
Published online 23 October 2023
  1. Marco Stief, “No-challenge and Pay-for-delay Agreements in Patent Licence and Settlement Agreements under European Competition Law,” Journal of Intellectual Property Law & Practice 18, no. 2 (2023): 135-145. [CrossRef] [Google Scholar]
  2. European Commission, Directorate-General for Competition, “Competition enforcement in the pharmaceutical sector (2009-2017): European competition authorities working together for affordable and innovative medicines,” Publications Office (2019), [Google Scholar]
  3. Federal Trade Commission, “Pay-for-delay: How drug manufacturer pay-offs cost consumers billions: A Federal Trade Commission staff study,” (August 5, 2021), [Google Scholar]
  4. China Pharmaceutical Industry Information Center, “China Generic Drug Development Report 2022 Edition,” (April 1, 2023) [Google Scholar]
  5. Supreme People’s Court, “AstraZeneca Ltd. vs. Jiangsu Osaikang Pharmaceutical Co., Ltd. Patent Infringement Dispute,” (2021) Final Civil Judgment No. 388 [Google Scholar]
  6. Nanjing Intermediate People’s Court of Jiangsu Province, “AstraZeneca Ltd. vs. Jiangsu Osaikang Pharmaceutical Co., Ltd. Patent Infringement Dispute,” (2019) Civil Judgment No. 1090 [Google Scholar]
  7. K. Lin, M. Lin, “Regulation Research on Reverse Payment Agreements of Pharmaceutical Patents,” Strait Law Review, 24(02), 70-76 (2022) [Google Scholar]
  8. M. Marmaro, “Molecule Size Doesn’t Matter: The Case for Harmonizing Antitrust Treatment of Pay-for-Delay Agreements,” Columbia J. Law Soc. Probl. 54, 169 (2021). [Google Scholar]
  9. U.S. Congress, “Medicare Prescription Drug, Improvement, and Modernization Act of 2003,” Public Law 108–173, 117 STAT. 2066, [Google Scholar]
  10. H. Su, “Anti-Monopoly of Drug Patent in U.S. Experience,” China Price Supervision and Anti-Monopoly, (03), 20-26 (2017) [Google Scholar]
  11. Competition DG, European Commission, “8th Report on the Monitoring of Patent Settlements,” (March 9, 2018), cals/inquiry/patent_settlements_report8_en.pdf [Google Scholar]
  12. Y. Cao, “Regulation of Reverse Payment Agreements in Drug Patent by Anti-Monopoly Law,” Hebei University, DOI:10.27103/d.cnki.ghebu.2020.000162 (2020) [Google Scholar]
  13. T. Pan, “Analysis of the Subject Qualification of Consumer Associations in Anti-Monopoly Civil Public Interest Litigation,” China Market Supervision Research, (01), 48-51 (2023) [Google Scholar]
  14. J. Wang, “China’s Anti-Monopoly Law Should Establish a Dual Enforcement System,” Legal Research, (05), 20-25 (2007) [Google Scholar]
  15. L. Yang, “Regulation of Reverse Payment Agreements in Drug Patent under the Perspective of Comparative Law,” Xinjiang Social Science, (05), 100-107 (2019) [Google Scholar]
  16. Supreme People’s Procuratorate, “Notice on Actively and Steadily Carrying out the Prosecution Work of Public Interest Litigation in the Anti-Monopoly Field” [Google Scholar]
  17. Z. Hu, “Exploration and Improvement Path of Anti-Monopoly Prosecution Civil Public Interest Litigation System,” China Price Supervision and Anti-Monopoly, (12), 37-42 (2022) [Google Scholar]
  18. Y. Chen, “Anti-Monopoly Civil Public Interest Litigation: The Road to Relief for Consumers Suffering Monopoly Damage,” Modern Law Science, 40(05), 130-144 (2018) [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.